Anya Borissova
Ketamine and suicidal ideation: French trial finds modest short-term effects
No Responses »
Anya Borissova reviews a French trial that claims to be evidence that “ketamine is rapid, safe in the short term, and has persistent benefits for acute care in suicidal patients”.
[read the full story...]How could MDMA-assisted and psilocybin-assisted psychotherapy help people with depression and PTSD?
Anya Borissova and Philip Brooks consider a recent review exploring MDMA-assisted psychotherapy and psilocybin-assisted psychotherapy for trauma-related mental health difficulties.
[read the full story...]Can ketamine metabolites and gamma power help predict clinical response for ‘treatment resistant depression’?
Anya Borissova summarises a recent randomised placebo-controlled trial that evaluated ketamine metabolites, clinical response, and gamma power for major depression.
[read the full story...]MDMA-assisted psychotherapy for alcohol use disorder: is it feasible?
Anya Borissova reviews a recent UK pilot study which suggests that MDMA-assisted psychotherapy is a feasible intervention to use in people with alcohol use disorder. Now we need randomised trials that can reliably measure safety and effectiveness.
[read the full story...]Psilocybin for treatment-resistant depression: what are the effects on brain activity?
Anya Borissova summarises the therapeutic mechanisms of psilocybin in treatment-resistant depression and changes noticed in the amygdala and prefrontal cortex during emotional processing.
[read the full story...]LSD: can psychedelics treat mental illness?
Anya Borissova summarises a recent systematic review which brings together all of the randomised controlled trials of LSD as a treatment for mental illnesses, including alcohol and heroin dependency, depression and anxiety.
[read the full story...]